PharmaForce investing $145M in Ohio sterile injectables operations

Syringe
CDMO PharmaForce, a unit of Japan's Daiichi Sankyo that makes sterile injectable drugs, is expanding its capacity at facilities in Ohio.

A U.S. unit of Japan’s Daiichi Sankyo that makes sterile injectable drugs is expanding its capacity at facilities inn Ohio, pledging to add nearly 80 jobs in the process.

CDMO PharmaForce will invest about $145 million to add 140,000 square feet to its New Albany, Ohio, manufacturing and warehouse operations, according to an announcement from development group Columbus 2020. It will also add about 1,800 square feet to a production facility in Hilliard, Ohio. Work is set to begin in the first quarter of 2018.

PharmaForce is a unit of Luitpold Pharmaceuticals, which also owns American Regent. Luitpold Pharmaceuticals, in turn, is a unit of Daiichi Sankyo.

The expansion comes as other contractors also are beefing up sterile injectable capacity. New Jersey-based Catalent recently agreed to pay $950 million to buy Cook Pharmica to get its extensive biologics manufacturing operation in Bloomington, Indiana.

AMRI has recently doubled its bulk API aseptic manufacturing capacity at a facility in Spain.

Suggested Articles

Gilead Sciences will add 140 jobs to its Irish operations as part of an expansion to its Dublin distribution center, the Irish Times reported.

Boehringer launches Shanghai innovation hub. Pharma shifts to digital amid COVID-19. Evolus and Daewoong hit a setback in a Botox trade secret suit.

GSK's Shingrix supply has recovered after COVID-19 prompted a slowdown in vaccinations.